Apricus Biosciences and Takeda Pharmaceuticals International, a top 20 big pharma company, have entered into an exclusive pharma partners agreement to market Vitaros, a treatment for erectile dysfunction, in the UK.
Under the terms of this pharma partners agreement, Takeda will pay NexMed a wholly owned subsidiary of Apricus Biosciences, an undisclosed upfront payment, and milestone payments of up to €35 million.
Vitaros is a topically delivered formulation (cream) of alprostadil (a vasodilator) supplied in a single dose dispenser (AccuDose), for the treatment of erectile dysfunction .
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Sexual Dysfunction Partnering
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity